Evolus EOLS
NASDAQ EOLS
$8.39 +0.04 (+0.48%)
At close: Aug 21, 2026 · 4:00 PM EDT

Evolus (EOLS) Short-term Investments (2019 - 2020)

Evolus' (EOLS) quarterly Short-term Investments came in at $5.0 million in Q4 2020, down 74.89% YoY from $19.9 million in Q1 2020, and down 80.0% on a QoQ basis from $25.0 million in Q3 2020.

Evolus (EOLS) Short-term Investments (2019 - 2020) Analysis & Trends

Evolus (EOLS) has 2 years of Short-term Investments data on file, last reported at $5.0 million in Q4 2020.

  • Quarterly Short-term Investments fell 74.89% year-over-year to $5.0 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $5.0 million (down 74.89% YoY) and the FY2020 annual result came in at $5.0 million, down 74.89% from the prior year.
  • Short-term Investments retreated to $5.0 million in Q4 2020, from $25.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $79.3 million in Q1 2019 to a low of $5.0 million in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Haleon 44.51 Bn 43.55 Bn -
2 Teva Pharmaceutical Industries 43.52 Bn 39.86 Bn 2.15 Bn
3 Zoetis 32.43 Bn 30.75 Bn 1.05 Bn
4 Takeda Pharmaceutical 28.63 Bn 22.83 Bn 5.10 Bn
5 United Therapeutics 21.87 Bn 19.21 Bn 683.80 Mn
6 Viatris 18.98 Bn 18.09 Bn 1.46 Bn
7 Neurocrine Biosciences 15.43 Bn 15.04 Bn 935.80 Mn
8 Elanco Animal Health 12.02 Bn 11.49 Bn 798.00 Mn
9 Dr Reddys Laboratories 10.14 Bn 9.98 Bn -
10 Evolus 552.49 Mn 507.32 Mn 57.18 Mn

Historic Data

Download Data
DateValue
Dec 31, 2020 5.00 Mn
Sep 30, 2020 25.00 Mn
Jun 30, 2020 54.98 Mn
Mar 31, 2020 64.99 Mn
Dec 31, 2019 19.91 Mn
Sep 30, 2019 34.91 Mn
Jun 30, 2019 69.64 Mn
Mar 31, 2019 79.31 Mn